IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Pancreatic Cancer: Likelihood of Approval
IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData's report assesses how IMM-47's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.IMM-47 overviewIMM-47 is under development for the treatment of solid tumors including ovarian cancer, esophageal cancer, breast cancer, lung cancer, colorectal cancer, hepatocellular cancer, pancreatic cancer, urothelial cancer, prostate cancer, and head and neck cancers. It is a monoclonal antibody (mAb) and acts by targeting CD24. It is administered through intravenous route. ImmuneOnco Biopharmaceuticals (Shanghai) overviewImmuneOnco Biopharmaceuticals (Shanghai) is an early stage biopharmaceutical company, engaged in the production and commercialization of innovative cancer immunotherapy products with the aim of reversing cancer cell-induced immune inhibition and actively eradicating cancer cells. The company is headquartered in Shanghai, China. For a complete picture of IMM-47's drug-specific PTSR and LoA scores, buy the report here.
IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Pancreatic Cancer.
What's Your Reaction?
